The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Panelists discuss how innovative approaches to symptom monitoring incorporate multifaceted technology and team-based strategies, including electronic patient-reported outcome tools integrated with ...

Panelists discuss how the new nilotinib formulation offers improved convenience by eliminating fasting requirements which may enhance adherence, while emphasizing that clinicians should remain ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...